Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW (2016) A phase 1b study of selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer 16: 153. D'...
By contrast, a manageable toxicity profile was reported at a dose of 75 mg BID selumetinib plus gemcitabine 1000 mg m−2 and cisplatin 25 mg m−2 in a Phase Ib trial in patients with advanced or metastatic biliary tract cancer (Bridgewater et al, 2016). However, this may ...